Modulation of tau phosphorylation by environmental copper

Translational Neurodegeneration - Tập 3 - Trang 1-10 - 2014
Kellen Voss1, Christopher Harris1, Martina Ralle2, Megan Duffy2, Charles Murchison1, Joseph F Quinn3,1
1Department of Neurology, Oregon Health and Sciences University, Portland, USA
2Department of Molecular and Medical Genetics, Oregon Health and Sciences University, Portland, USA
3Department of Neurology and Parkinson’s Disease Research Education and Clinical Care Center (PADRECC), Portland Veterans Affairs Medical Center, Portland, USA

Tóm tắt

The transition metal copper enhances amyloid β aggregation and neurotoxicity, and in models of concomitant amyloid and tau pathology, copper also promotes tau aggregation. Since it is not clear if the effects of environmental copper upon tau pathology are dependent on the presence of pathological amyloid β, we tested the effects of copper overload and complexing in disease models which lack pathological amyloid β. We used cell culture and transgenic murine models to test the effects of environmental copper on tau phosphorylation. We used oral zinc acetate as a copper lowering agent in mice and examined changes in blood and brain metals through inductively coupled plasma mass spectroscopy. Behavioral effects of copper lowering were assessed with Morris water maze and novel object recognition tasks. Changes in tau phosphorylation were examined by phosphorylation specific antibodies on Western blots. In human neuroblastoma cells, excess copper promoted tau phosphorylation and a copper complexing agent, tetrathiomolybdate, attenuated tau phosphorylation. In a transgenic mouse model expressing wild type human tau, copper-lowering by oral zinc suppressed plasma and brain levels of copper, and resulted in a marked attenuation of tau phosphorylation. No significant changes in behavior were observed with copper lowering, but a trend to improved recognition of the novel object was observed in zinc acetate treated mice. We propose that reduction of brain copper by blocking uptake of copper from the diet may be a viable strategy for modulating tau pathology in Alzheimer’s disease. The potential benefits of this approach are tempered by the absence of a behavioral benefit and by the health risks of excessive lowering of copper.

Tài liệu tham khảo

Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX: Overexpression of Alzheimer’s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002, 277(47):44670-44676.

Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL: A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem 1993, 268(22):16109-16112.

Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001, 30(3):665-676.

Kitazawa M, Cheng D, Laferla FM: Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 2009, 108(6):1550-1560.

Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003, 60(12):1685-1691.

Tabira T: Clioquinol’s return: cautions from Japan. Science 2001, 292(5525):2251-2252.

Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI: Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999, 274(52):37111-37116.

Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI: The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38(24):7609-7616.

Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA: In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals. J Neurochem 2000, 74(1):270-279.

Ma Q, Li Y, Du J, Liu H, Kanazawa K, Nemoto T, Nakanishi H, Zhao Y: Copper binding properties of a tau peptide associated with Alzheimer’s disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006, 27(4):841-849.

Ma QF, Li YM, Du JT, Kanazawa K, Nemoto T, Nakanishi H, Zhao YF: Binding of copper (II) ion to an Alzheimer’s tau peptide as revealed by MALDI-TOF MS, CD, and NMR. Biopolymers 2005, 79(2):74-85.

Martic S, Rains MK, Kraatz HB: Probing copper/tau protein interactions electrochemically. Anal Biochem 2013, 442(2):130-137.

Soragni A, Zambelli B, Mukrasch MD, Biernat J, Jeganathan S, Griesinger C, Ciurli S, Mandelkow E, Zweckstetter M: Structural characterization of binding of Cu(II) to tau protein. Biochemistry 2008, 47(41):10841-10851.

Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI: Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59(1):43-55.

Deacon RM, Cholerton LL, Talbot K, Nair-Roberts RG, Sanderson DJ, Romberg C, Koros E, Bornemann KD, Rawlins JN: Age-dependent and -independent behavioral deficits in Tg2576 mice. Behav Brain Res 2008, 189(1):126-138.

Quinn JF, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, Wadsworth TL: A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 2010, 21(3):903-914.

Harris CJ, Voss K, Murchison C, Ralle M, Frahler K, Carter R, Rhoads A, Lind B, Robinson E, Quinn JF: Oral zinc reduces amyloid burden in Tg2576 mice. J Alzheimers Dis 2014, 41(1):179-192.

Ferenci P: Wilson’s disease. Clin Gastroenterol Hepatol 2005, 3(8):726-733.

Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM, Sensi SL: Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis 2010, 1: e91.

Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M: An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 2010, 20(4):1069-1082.

Arciello M, Rotilio G, Rossi L: Copper-dependent toxicity in SH-SY5Y neuroblastoma cells involves mitochondrial damage. Biochem Biophys Res Commun 2005, 327(2):454-459.

Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX: Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000, 75(3):991-1003.

Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123(11):1939-1951.

Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J: Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006, 63(4):521-527.

Schosinsky KH, Lehmann HP, Beeler MF: Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974, 20(12):1556-1563.

Woltjer RL, Cimino PJ, Boutte AM, Schantz AM, Montine KS, Larson EB, Bird T, Quinn JF, Zhang J, Montine TJ: Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer’s disease. Faseb J 2005, 19(13):1923-1925.

Stoltenberg M, Bush AI, Bach G, Smidt K, Larsen A, Rungby J, Lund S, Doering P, Danscher G: Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 2007, 150(2):357-369.

An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ: Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 2005, 92(5):1104-1115.

Boom A, Authelet M, Dedecker R, Frederick C, Van Heurck R, Daubie V, Leroy K, Pochet R, Brion JP: Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochim Biophys Acta 2009, 1793(6):1058-1067.

Xiong Y, Jing XP, Zhou XW, Wang XL, Yang Y, Sun XY, Qiu M, Cao FY, Lu YM, Liu R, Wang JZ: Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging 2013, 34(3):745-756.

Sun XY, Wei YP, Xiong Y, Wang XC, Xie AJ, Wang XL, Yang Y, Wang Q, Lu YM, Liu R, Wang JZ: Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem 2012, 287(14):11174-11182.

Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR: Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998, 158(1):47-52.

Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J: Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease. J Struct Biol 2006, 155(1):30-37.

Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Murjoni M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li Q, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ: Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 2009, 106(2):381-386.

Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE: Treatment of Wilson’s disease with zinc. I. Oral zinc therapy regimens. Hepatology 1987, 7(3):522-528.

Thông tin
Thông tin xuất bản

Translational Neurodegeneration

Tập 3

1-10

Thông tin tác giả